The global Value-added Medicines (VAM) market size is predicted to grow from US$ 748 million in 2025 to US$ 1451 million in 2031; it is expected to grow at a CAGR of 11.7% from 2025 to 2031.

Value-added medicines offer the medical world the opportunity to increase the quality of treatments as well as expand access to healthcare for more people. By improving the efficiency of the healthcare system, value-based healthcare contributes to its sustainability, addresses inefficiencies related to medicines, and offers economic advantages to all parties involved in medical treatments.Value-added medicines are drug products and treatments created using known molecules through a process known as drug repositioning. The purpose of these innovative medicines is to create improvements in the quality of patient care.Value-based treatment options give patients more agency to manage their ailments, leading to improved patient adherence, quality of life, and health outcomes. Likewise, improved treatments prevent medical conditions to escalate to serious levels. This lightens the burden that patients in critical condition put on healthcare systems, giving doctors and nurses some much-needed breathing space.

United States market for Value-added Medicines (VAM) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Value-added Medicines (VAM) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Value-added Medicines (VAM) is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Value-added Medicines (VAM) players cover Zentiva Group, MS Pharma, Towa International, CNX Therapeutics, ROVI, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information) newest research report, the ?Value-added Medicines (VAM) Industry Forecast? looks at past sales and reviews total world Value-added Medicines (VAM) sales in 2024, providing a comprehensive analysis by region and market sector of projected Value-added Medicines (VAM) sales for 2025 through 2031. With Value-added Medicines (VAM) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Value-added Medicines (VAM) industry.

This Insight Report provides a comprehensive analysis of the global Value-added Medicines (VAM) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Value-added Medicines (VAM) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Value-added Medicines (VAM) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Value-added Medicines (VAM) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Value-added Medicines (VAM).

This report presents a comprehensive overview, market shares, and growth opportunities of Value-added Medicines (VAM) market by product type, application, key players and key regions and countries.

Segmentation by Type:

    Chronic Disease Treatment Drugs
    Infectious Disease Treatment Drugs
    Tumor Treatment Drugs
    Other

Segmentation by Application:

    Hospital
    Clinic
    Other

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the companys coverage, product portfolio, its market penetration.

    Zentiva Group
    MS Pharma
    Towa International
    CNX Therapeutics
    ROVI
    Elpen
    Sandoz AG
    Colonis
    Adamed
    Hyloris Pharmaceuticals SA
    TIEFENBACHER GROUP